改变EGFR突变NSCLC患者的治疗和转移性疾病模式:一个学术胸部医学研究者联盟注册表分析
Margaret Stalker1, Connor B Grady2, Alex Watts2
1Department of Medicine, Perelman School of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania.
JTO clinical and research reports
|January 6, 2025
概括
即使使用奥西默蒂尼布,脑转移仍然是EGFR突变非小细胞肺癌患者的高风险. 建议进行常规的大脑MRI监测,因为大脑转移与严重的生存损害有关.
科学领域:
- 在瘤学瘤学.
- 医学胸部瘤学 医学胸部瘤学
- 临床研究 临床研究
背景情况:
- 奥西默提尼布是EGFR突变 (EGFRm) 晚期非小细胞肺癌 (NSCLC) 的标准一线治疗方法.
- 描述治疗模式和转移风险对于优化患者的治疗结果至关重要.
研究的目的:
- 分析EGFRm NSCLC中的治疗模式.
- 为了确定EGFRm NSCLC患者大脑和肝脏转移的纵向风险.
主要方法:
- 对1132名EGFRmNSCLC患者的回顾性分析.
- 用于生存和转移分析的Kaplan-Meier,Cox回归和累积发病率函数.
- 专注于从2015年起开始第一线治疗的患者.
主要成果:
- 2018年后,奥西默提尼布的使用量显著增加.
- 下一次治疗的中位时间为13.9个月, osimertinib (28个月) 最长.
- 在2015年后的队列中,54%的人有基线大脑转移 (BM);48个月后发生的BM概率为44%,没有基线BM. 在治疗期间,BM增加了3.2倍的死亡风险.
结论:
- 尽管有 osimertinib,大脑转移的高基线和纵向风险仍然存在.
- 大脑转移的发展显著恶化了EGFRm NSCLC的存活率.
- 对于EGFRm NSCLC患者,需要进行常规的大脑MRI监测.
更多相关视频
09:38Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure
Published on: August 11, 2017
8.7K
09:38Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib
Published on: June 26, 2019
7.8K
相关概念视频
Mitogens and the Cell Cycle
6.3K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.3K
Targeted Cancer Therapies
7.4K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.4K
Metastasis
5.4K
Metastasis is the spread of cancer cells from the original site to distant locations in the body. Cancer cells can spread via blood vessels (hematogenous) as well as lymph vessels in the body.
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
5.4K
